Shire Plc (SHP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9971)
◆英語タイトル:Shire Plc (SHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9971
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:253
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to treat patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc (SHP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 10
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Shire Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Shire Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Shire Plc, Medical Devices Deals, 2012 to YTD 2018 16
Shire Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Shire Plc, Pharmaceuticals & Healthcare, Deal Details 25
Asset Purchase 25
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 25
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 26
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 27
Venture Financing 28
Rani Therapeutics Raises USD53 Million in Venture Financing 28
OncoResponse Raises Additional USD3 Million in Series A Financing 29
Promethera Biosciences Raises USD25 Million in Series C Venture Financing 31
Naurex Raises US$25 Million In Venture Financing 33
NeuroPhage Pharma Raises US$17 Million In Series D Financing 35
Lumena Pharma Raises US$45 Million In Series B Financing 36
Foresight Biotherapeutics Raises US$15 Million In Venture Financing 38
Suppremol Raises US$20.6 Million In Series D Financing 39
AesRx Raises US$1.35 Million In Venture Financing 40
Lumena Pharma Raises US$23 Million In Series A Financing 41
NeuroPhage Pharma Raises US$6.4 Million In Series C Financing 42
Ultragenyx Pharma Raises US$75 Million In Series B Financing 43
Naurex Raises US$38 Million In Series B Financing 45
ArmaGen Technologies Raises US$17 Million In Series A Financing 47
bluebird bio Raises US$60 Million In Series D Financing 49
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing 51
NeuroPhage Pharma Raises US$9 Million In Series B-1 Financing 52
FerroKin Biosciences Raises US$3 Million In Venture Financing 53
Lumena Pharma Raises US$2.05 Million In Final Tranche Of Venture Financing 54
Partnerships 55
Pint Pharma Enters into Licensing Agreement with Dyax 55
Shire and NanoMedSyn Enter into Research Agreement 56
Dover Life Sciences Enters into Research Collaboration Agreement with Shire 57
PatientsLikeMe Enters into Agreement with Shire 58
Generium Forms Joint Venture with Shire 59
Baxalta Enters into Agreement with Precision Biosciences 60
Baxalta Enters into Agreement with Symphogen 61
Novimmune Enters into Research Agreement with Baxalta 62
Shire Enters into Research Agreement with Foundation Fighting Blindness 63
Shire Enters into Research Agreement with Cincinnati Children’s Hospital 64
Cystic Fibrosis Foundation Therapeutics Enters into Research Agreement with Shire 65
Prasco Labs Enters Into Agreement With Shire For Distribution Of Fosrenol 66
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 67
Nimbus Discovery Enters Into Co-Development Agreement With Shire 68
Ethris Enters Into Agreement With Shire Human Genetic Therapies For RNA-Based Therapeutics 69
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics 70
Shire Enters Into Co-Development Agreement With Boston Children’s Hospital For Pediatric Therapies 71
Shire Enters Into Research Agreement With Fondazione Telethon 72
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 73
ViroPharma Enters Into Co-Marketing Agreement With Prasco Labs For Vancocin 74
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 75
Prasco Labs Enters Into Co-Marketing Agreement With Shire For Carbatrol 76
Licensing Agreements 77
Mirum Pharma Enters into Licensing Agreement with Shire 77
Caladrius Biosciences Enters into Licensing Agreement with Shire 78
Shire Enters into Licensing Agreement with AB Biosciences 79
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 80
Shire Enters into Licensing Agreement with Novimmune 81
Shire Enters into Licensing Agreement with Parion Sciences for P-321 82
Neos Therapeutics Enters into Licensing Agreement with Shire 83
Shire Enters into Licensing Agreement with Pfizer 84
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 85
Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma 86
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 87
Dyax Amends Licensing Agreement With CVie Therapeutics For Kalbitor 89
Shire Enters into License agreement with IGAN Biosciences 90
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 91
Dyax Enters Enters into Licensing Agreement with Kadmon 92
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 93
Premacure Amends Licensing Agreement with Insmed 94
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody 95
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 96
Shire Extends its Licensing Agreement with ArGEN-X 97
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 99
Dyax Enters Into Licensing Agreement With Novellus Biopharma For Kalbitor 101
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 102
GE Healthcare Enters Into Licensing Agreement With Dyax For c-Met Imaging Peptides 103
Equity Offering 104
Shire Plans to Spin Out its Neuroscience Franchise 104
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 105
Baxalta Invests in OncoResponse 106
Dyax Raises USD230 Million in Public Offering of Shares 107
Lumena Pharma Withdrawn IPO 109
Dyax Completes Public Offering Of Shares For US$85 Million 110
Dyax Completes Public Offering Of Shares For US$69 Million 111
NPS Pharma Completes Public Offering Of Shares For US$100 Million 112
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 113
Dyax Completes Private Placement Of Shares For US$20.5 Million 115
Debt Offering 117
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 117
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 119
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 121
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 123
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 125
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 126
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 127
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 128
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 129
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 130
Asset Transactions 131
Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 131
Lonza to Acquire Mammalian Manufacturing Site from Shire 133
RaNA Therapeutics Acquires MRT Platform from Shire 134
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies 135
Chronos Therapeutics Acquires Pre-Clinical Programmes from Shire 136
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 137
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 138
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 139
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 140
Organogenesis Acquires Dermagraft From Shire For USD300 Million 142
Acquisition 144
Takeda Pharma to Acquire Shire 144
Shire May Acquire Radius Health 147
Shire Acquires Baxalta for USD32 Billion 148
Shire Acquires Dyax 150
Shire Acquires Foresight Biotherapeutics 152
Actelion Rejects Acquisition Offer from Shire 153
Baxter International Acquires SuppreMol for USD225 Million 154
Shire Acquires NPS Pharma for USD5.2 Billion 155
ViroPharma Completes Acquisition of Meritage Pharma for USD245 Million 157
Baxter Acquires AesRx 158
Shire Acquires BIKAM Pharma 159
Shire Acquires Lumena Pharma From RiverVest Venture Partners 160
Shire To Acquire Fibrotech Therapeutics, Biotech Company, For US$75 Million 161
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma 163
AstraZeneca May Acquire Ariad Pharma 164
Shire Completes Acquisition Of Majority Interest In ViroPharma For US$2.7 Billion 166
Shire Acquires Sarcode Bioscience For up to USD675 Million 168
Shire Acquires Premacure, Protein Replacement Therapy Developer 170
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 171
AstraZeneca Reportedly Mulls Acquisition of Shire 172
Shire Acquires Pervasis Therapeutics for USD196 Million 173
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 175
Shire Plc – Key Competitors 177
Shire Plc – Key Employees 178
Shire Plc – Locations And Subsidiaries 179
Head Office 179
Other Locations & Subsidiaries 179
Joint Venture 186
Recent Developments 187
Strategy And Business Planning 187
Apr 27, 2017: Shire opens new HQ office in Dublin City Centre 187
Financial Announcements 188
Nov 01, 2018: Shire delivers product sales growth of 6% and continues to execute against key priorities in Q3 2018 188
Jul 31, 2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress 191
Apr 26, 2018: Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018 193
Feb 14, 2018: Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017 195
Oct 27, 2017: Shire Reports Strong Earnings Growth in Q3 2017; Reiterates Full Year Guidance 197
Aug 03, 2017: Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance 200
May 02, 2017: Shire delivers strong Q1 2017 revenue growth while advancing late-stage pipeline 204
Feb 16, 2017: Shire Announces Full Year 2016 Results 209
Corporate Communications 212
Jul 25, 2018: Shire announces Director declaration 212
Mar 22, 2018: Shire Commits to Long-Term Responsibility Goals in 2017 Annual Responsibility Review 213
Jan 19, 2018: Shire: Directorate Change 214
Jan 02, 2018: Shire: Director Declaration 215
Dec 19, 2017: Shire:Director Declaration 216
Dec 08, 2017: Chief Financial Officer update 217
Dec 08, 2017: Shire: Chief Financial Officer update 218
Dec 01, 2017: Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer 219
Nov 20, 2017: Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of Directors 220
Aug 21, 2017: Shire Director and Senior Management Changes 221
Jan 13, 2017: Shire Joins Illinois Biotechnology Innovation Organization as Leadership Sponsor and Adds Shannon Resetich to the Board 222
Legal and Regulatory 223
Mar 13, 2018: Shire Applies to Cease to be a Reporting Issuer in Canada 223
Dec 27, 2017: Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise 224
Feb 07, 2017: Shire Responds to US Federal Trade Commission Civil Action 225
Government and Public Interest 226
Sep 11, 2018: NORD announces ten new rare disease registries, thanks to multi-year grant from Shire 226
Jan 23, 2018: Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for Publication of Shire-Supported Research 227
Product News 228
Dec 14, 2017: Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients Through Innovative Personalized Treatment 228
06/23/2017: Shire to present data on SHP648 at ISTH 2017 to advance the standard of care in Hemophilia 230
06/21/2018: Shire Announces FDA Approval for Label Expansion of CINRYZE for Prevention of Attacks in Pediatric HAE 231
05/26/2017: Attention deficit/hyperactivity disorder therapeutic agent ‘INTUNIV Tablets 1 mg/3 mg’ launched in Japan 232
05/19/2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology 233
04/26/2017: Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism 234
03/30/2017: INTUNIV (guanfacine hydrochloride prolonged release), a non-stimulant for the treatment of ADHD, receives approval in Japan 235
03/16/2017: Shire Receives European Approval for Label Extension of CINRYZE to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE 236
02/24/2017: First hormone replacement therapy for parathyroid disorder 238
02/15/2018: Shire Announces FDA Acceptance of sBLA for CINRYZE (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use 239
01/24/2017: FDA Grants Approval to Shire for Technology Transfer of CINRYZE (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site 240
01/15/2018: European Medicines Agency: Defect with Buccolam oral syringes 241
01/06/2017: Xenetic Biosciences Receives $3 Million Milestone Payment from Shire for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia 242
01/03/2018: Xiidra (Lifitegrast Ophthalmic Solution 5%) Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease 243
01/03/2017: Xenetic Biosciences to Present at Biotech Showcase 2017 244
Product Approvals 245
Aug 15, 2017: Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe 245
Jul 07, 2017: Shire Japan Files Hereditary Angioedema Drug Icatibant 246
Feb 14, 2017: Shire Seeks Approval of Lifitegrast in Canada for the Treatment of Dry Eye Disease in Adults 247
Clinical Trials 248
Sep 20, 2017: Shire and Shionogi Announce Positive Topline Results for INTUNIV Evaluated in Phase 3 Clinical Trial in Adults with ADHD 248
Sep 11, 2017: Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial 249
Other Significant Developments 250
May 30, 2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials 250
Jan 08, 2018: Shire announces business update at 36th Annual J.P. Morgan Healthcare Conference 251
Appendix 253
Methodology 253
About GlobalData 253
Contact Us 253
Disclaimer 253

List of Tables
Shire Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Shire Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Shire Plc, Deals By Therapy Area, 2012 to YTD 2018 14
Shire Plc, Medical Devices Deals, 2012 to YTD 2018 16
Shire Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 25
Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 26
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 27
Rani Therapeutics Raises USD53 Million in Venture Financing 28
OncoResponse Raises Additional USD3 Million in Series A Financing 29
Promethera Biosciences Raises USD25 Million in Series C Venture Financing 31
Naurex Raises US$25 Million In Venture Financing 33
NeuroPhage Pharma Raises US$17 Million In Series D Financing 35
Lumena Pharma Raises US$45 Million In Series B Financing 36
Foresight Biotherapeutics Raises US$15 Million In Venture Financing 38
Suppremol Raises US$20.6 Million In Series D Financing 39
AesRx Raises US$1.35 Million In Venture Financing 40
Lumena Pharma Raises US$23 Million In Series A Financing 41
NeuroPhage Pharma Raises US$6.4 Million In Series C Financing 42
Ultragenyx Pharma Raises US$75 Million In Series B Financing 43
Naurex Raises US$38 Million In Series B Financing 45
ArmaGen Technologies Raises US$17 Million In Series A Financing 47
bluebird bio Raises US$60 Million In Series D Financing 49
PROMETHERA Biosciences Raises US$31.5 Million In Series B Financing 51
NeuroPhage Pharma Raises US$9 Million In Series B-1 Financing 52
FerroKin Biosciences Raises US$3 Million In Venture Financing 53
Lumena Pharma Raises US$2.05 Million In Final Tranche Of Venture Financing 54
Pint Pharma Enters into Licensing Agreement with Dyax 55
Shire and NanoMedSyn Enter into Research Agreement 56
Dover Life Sciences Enters into Research Collaboration Agreement with Shire 57
PatientsLikeMe Enters into Agreement with Shire 58
Generium Forms Joint Venture with Shire 59
Baxalta Enters into Agreement with Precision Biosciences 60
Baxalta Enters into Agreement with Symphogen 61
Novimmune Enters into Research Agreement with Baxalta 62
Shire Enters into Research Agreement with Foundation Fighting Blindness 63
Shire Enters into Research Agreement with Cincinnati Children's Hospital 64
Cystic Fibrosis Foundation Therapeutics Enters into Research Agreement with Shire 65
Prasco Labs Enters Into Agreement With Shire For Distribution Of Fosrenol 66
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 67
Nimbus Discovery Enters Into Co-Development Agreement With Shire 68
Ethris Enters Into Agreement With Shire Human Genetic Therapies For RNA-Based Therapeutics 69
Arrowhead Research Enters Into Agreement With Shire To Develop Peptide-Targeted Therapeutics 70
Shire Enters Into Co-Development Agreement With Boston Children's Hospital For Pediatric Therapies 71
Shire Enters Into Research Agreement With Fondazione Telethon 72
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 73
ViroPharma Enters Into Co-Marketing Agreement With Prasco Labs For Vancocin 74
Argen-X Expands Co-Development Agreement With Shire For Additional Therapeutic Antibody 75
Prasco Labs Enters Into Co-Marketing Agreement With Shire For Carbatrol 76
Mirum Pharma Enters into Licensing Agreement with Shire 77
Caladrius Biosciences Enters into Licensing Agreement with Shire 78
Shire Enters into Licensing Agreement with AB Biosciences 79
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 80
Shire Enters into Licensing Agreement with Novimmune 81
Shire Enters into Licensing Agreement with Parion Sciences for P-321 82
Neos Therapeutics Enters into Licensing Agreement with Shire 83
Shire Enters into Licensing Agreement with Pfizer 84
Shire Enters into Licensing Agreement with ArmaGen for AGT-182 85
Shire Human Genetic Enters into Licensing Agreement with Biomarin Pharma 86
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 87
Dyax Amends Licensing Agreement With CVie Therapeutics For Kalbitor 89
Shire Enters into License agreement with IGAN Biosciences 90
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 91
Dyax Enters Enters into Licensing Agreement with Kadmon 92
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 93
Premacure Amends Licensing Agreement with Insmed 94
Dyax Enters Into Licensing Agreement With Eclipse Therapeutics For Oncology Antibody 95
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 96
Shire Extends its Licensing Agreement with ArGEN-X 97
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 99
Dyax Enters Into Licensing Agreement With Novellus Biopharma For Kalbitor 101
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 102
GE Healthcare Enters Into Licensing Agreement With Dyax For c-Met Imaging Peptides 103
Shire Plans to Spin Out its Neuroscience Franchise 104
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 105
Baxalta Invests in OncoResponse 106
Dyax Raises USD230 Million in Public Offering of Shares 107
Lumena Pharma Withdrawn IPO 109
Dyax Completes Public Offering Of Shares For US$85 Million 110
Dyax Completes Public Offering Of Shares For US$69 Million 111
NPS Pharma Completes Public Offering Of Shares For US$100 Million 112
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 113
Dyax Completes Private Placement Of Shares For US$20.5 Million 115
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 117
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 119
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 121
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 123
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 125
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 126
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 127
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 128
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 129
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 130
Les Laboratoires Servier Acquires Oncology Business from Shire for USD2.4 Billion 131
Lonza to Acquire Mammalian Manufacturing Site from Shire 133
RaNA Therapeutics Acquires MRT Platform from Shire 134
Translate Bio to Acquire mRNA Therapy Platform from Shire Human Genetic Therapies 135
Chronos Therapeutics Acquires Pre-Clinical Programmes from Shire 136
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 137
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 138
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 139
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 140
Organogenesis Acquires Dermagraft From Shire For USD300 Million 142
Takeda Pharma to Acquire Shire 144
Shire May Acquire Radius Health 147
Shire Acquires Baxalta for USD32 Billion 148
Shire Acquires Dyax 150
Shire Acquires Foresight Biotherapeutics 152
Actelion Rejects Acquisition Offer from Shire 153
Baxter International Acquires SuppreMol for USD225 Million 154
Shire Acquires NPS Pharma for USD5.2 Billion 155
ViroPharma Completes Acquisition of Meritage Pharma for USD245 Million 157
Baxter Acquires AesRx 158
Shire Acquires BIKAM Pharma 159
Shire Acquires Lumena Pharma From RiverVest Venture Partners 160
Shire To Acquire Fibrotech Therapeutics, Biotech Company, For US$75 Million 161
Baxter International Acquires Chatham Therapeutics from Asklepios BioPharma 163
AstraZeneca May Acquire Ariad Pharma 164
Shire Completes Acquisition Of Majority Interest In ViroPharma For US$2.7 Billion 166
Shire Acquires Sarcode Bioscience For up to USD675 Million 168
Shire Acquires Premacure, Protein Replacement Therapy Developer 170
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 171
AstraZeneca Reportedly Mulls Acquisition of Shire 172
Shire Acquires Pervasis Therapeutics for USD196 Million 173
Shire Completes Acquisition of Ferrokin Biosciences For Up To US$320 Million 175
Shire Plc, Key Competitors 177
Shire Plc, Key Employees 178
Shire Plc, Other Locations 179
Shire Plc, Subsidiaries 179
Shire Plc, Joint Venture 186

List of Figures
Shire Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Shire Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12
Shire Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Shire Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Shire Plc, Medical Devices Deals, 2012 to YTD 2018 16

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Shire Plc (SHP):製薬・医療:M&Aディール及び事業提携情報(Shire Plc (SHP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆